Acute myeloid leukemia (AML) is a leading cause of cancer-related deaths in young adults and a highly lethal disease in older adults. Most AML patients do not survive longer than two years.

The Leucegene project will help pave the way for a new era in personalized medicine and offer patients better targeted therapies. We envision higher cure rates and longer, disease-free lifespans for AML patients.


Next-generation sequencing, chemogenomic and precision medicine approaches to cure AML

Health Care Providers

Driving new prognostic tests to the clinic through socio-economic studies and clinician engagement


Delivering precision medicine for AML to provide cures for this disease


$12.8 million for Leucegene Research

Guy Sauvageau, Josée Hébert and the Leucegene team are awarded…

New publication in Leukemia

Transcriptomic landscape of acute promyelocytic leukemia reveals…

Our Partners